Hook / Thesis
Rocket Lab (RKLB) has swung from a $151 52-week high to the mid-$60s, and today that volatility is an investor opportunity, not just noise. The company remains one of the few public players with an integrated play across launch services and spacecraft systems, and its pending Iridium acquisition plus fresh U.S. Space Force work give the stock real, event-driven upside.
I'm upgrading RKLB to a tactical long. The setup is simple: a constructive technical base around $64-$67, a string of meaningful catalysts over the next 12-18 months, and a valuation gap that the market can begin to narrow if the Iridium deal closes and revenue conversion continues. This is a mid-term, catalyst-driven swing with a disciplined stop.
What Rocket Lab does and why it matters
Rocket Lab is a vertically integrated space infrastructure company operating two main segments: Launch Services and Space Systems. Launch Services sells dedicated and rideshare launches. Space Systems designs, builds and operates spacecraft, components and on-orbit services. That hybrid model matters because launch is a growth engine while space systems deliver higher margin recurring revenue and programmatic backlog.
The market should care because Rocket Lab is not a pure-play launch vendor or a small component shop. It sits in the sweet spot of the commercial and national-security space value chains: reusable medium-lift rockets and a growing business building satellites and optical communications payloads. That mix gives Rocket Lab optionality across defense contracts, commercial constellations and aftermarket services.
Concrete data points that support the trade
- Market capitalization is roughly $39.4 billion, with shares outstanding ~598.5 million and a float near 589.3 million.
- Revenue momentum: Recent commentary pointed to 62% year-over-year Q2 sales growth and a record 90-launch backlog, signaling strong top-line conversion potential.
- Iridium acquisition: The planned purchase of Iridium would add ~$884 million in annual revenue with ~72% gross margins, a transformational scale-up expected to move the combined company to profitability and positive free cash flow in 2027.
- Balance-sheet and cash flow: Free cash flow remains negative (reported -$371.139 million), but leverage is low (debt-to-equity ~0.01), leaving operational execution—and the timing of the Iridium deal—as the critical cash story.
- Technicals favor a recovery entry: the 10-day SMA sits near $64.85 and the 9-day EMA is $65.64 while RSI is neutral at ~40, indicating room to run without immediate overbought risk.
Valuation framing - expensive today, but context matters
On headline multiples RKLB is expensive: price-to-sales is above 53 and EV-to-sales is ~50.7. The trailing P/E is negative (-229.8) due to the current operating losses. Those metrics look punitive until you factor the Iridium deal. If an $8 billion acquisition brings in $884 million at roughly 72% gross margin, the consolidated company could flip to positive EBITDA and materially change the narrative—turning multiples from forward-loss to earnings-based calculations.
So the valuation is a two-state problem: (A) pre-Iridium the company is a high-growth but unprofitable business trading at a premium on optionality, and (B) post-Iridium the company becomes scaled with margin profile and cash flow that justify a very different multiple. This trade banks on the market starting to price in state B over the coming months if catalysts check out.
Catalysts to drive the move
- Iridium merger progress - closing is expected mid-2027 and will be the single largest structural catalyst for profitability and valuation re-rating.
- U.S. Space Force work - selection for the Space Data Network Consortium and two delivery orders worth $12 million (announced 09/07/2026) validate defense revenue potential and could lead to more wide-scoped contracts.
- Launch cadence and backlog conversion - the 90-launch backlog underpins predictable revenue for Launch Services as Electron and (eventually) Neutron activity ramps.
- Operational updates - any progress on Neutron pad delivery (now targeting Q4 2026 for pad delivery, with launch likely in 2027) or revenue beats would be incremental positive surprises.
Trade plan (entry, stop, targets) - mid-term swing
| Action | Price | Horizon |
|---|---|---|
| Entry | $66.00 | Mid term (45 trading days) - time to let catalysts and M&A progress show through |
| Stop loss | $60.00 | |
| Primary target | $85.00 |
Why this plan? Entry at $66 is within the current trading band and right above short-term support defined by the 10-day SMA and recent intraday lows. The stop at $60 cuts through the recent consolidation zone and limits downside if the market re-prices the company's growth prospects. A target of $85 represents a ~29% upside and is a practical mid-term objective as the market re-assesses the Iridium synergies and near-term contract wins.
Position sizing note: treat this as a single swing allocation and size accordingly to your risk tolerance (stop-to-entry is $6 per share on this plan). Do not over-leverage while Neutron timing and the Iridium close remain in play.
Risks and counterarguments
- Valuation stretch: The stock already prices in future growth and the Iridium deal; multiples (P/S > 53, EV/S > 50) leave little room for missteps. If the market demands proof-of-earnings before re-rating, further downside is possible.
- Neutron delays and execution risk: Neutron pad delivery is now targeted for Q4 2026 with launch likely in 2027. Additional slips would push revenue and margin realization farther out and could trigger volatility.
- M&A integration risk: The Iridium acquisition is transformational but complex. Deal execution, regulatory approvals, and integration missteps could erode the expected synergy contribution and delay profitability.
- Cash burn and financing risk: Free cash flow is negative (reported -$371.139 million). Even with low leverage, extended negative cash flow could force dilutive financing if the Iridium timeline slips or contract revenue does not convert.
- Insider selling and perception: The CFO sold ~140,157 shares through a pre-planned 10b5-1 arrangement on 09/02/2026. While pre-planned sales happen, headlines can weigh on sentiment and amplify short-term weakness.
- Macro and sentiment shocks: Space stocks can be correlation victims in risk-off periods. A broader sell-off or a sector rotation could negate company-specific positives temporarily.
Counterargument: The most valid opposing view is that valuation is simply too rich for a company that still burns cash and has a significant product milestone (Neutron) at risk of slipping into 2027. If you believe the market will insist on sustained profitability from organic operations before rewarding M&A optionality, sitting on the sidelines makes sense.
Why I still like the trade
Two offsetting forces make this a compelling tactical buy: (1) high-probability government wins and specialty defense work (such as the Space Data Network orders) create steady, non-dilutive revenue that is easier to book and defend; (2) the Iridium transaction materially changes the financial profile and can flip the narrative from 'promised future optionality' to 'scaled company with strong margins.' Those are the kinds of binary shifts that attract money into beaten-down momentum names and compress downside risk.
What would change my mind
- If the Iridium deal fails to clear regulatory or shareholder approval, I would close this trade immediately or tighten stops aggressively.
- If Rocket Lab reports a substantial miss to revenue guidance or materially increases near-term dilution plans, I would abandon the long thesis.
- If Neutron execution collapses into a multi-year delay, the risk-reward would no longer be attractive and I would reassess to either move to the sidelines or switch to a longer-term, event-driven hold only on proof of integration progress.
Conclusion
Rocket Lab is a high-conviction but event-driven trade. At $66 entry with a $60 stop and $85 target, the mid-term trade captures upside tied to Iridium and defense contract wins while containing downside if the story falters. The stock is not a passive long for every portfolio—its valuation and execution risks demand strict risk management—but for traders who size the position responsibly, the current pullback offers an asymmetric opportunity.
Execute with discipline, watch the merger timetable and defense contract progress, and be prepared to tighten or exit if the company misses its operational beats.